|
Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified |
Sep. 30, 2014
|
Jun. 30, 2014
|
|---|---|---|
| Significant Accounting Policies [Line Items] | ||
| Available-for-sale securities, fair value | $ 36.1 | $ 48.4 |
| Available-for-sale securities, amortized cost | 37.1 | 40.7 |
| Excess protein antibody and chemically-based inventory | 30 | 30 |
|
Chemo Centryx, Inc.
|
||
| Significant Accounting Policies [Line Items] | ||
| Available-for-sale securities, fair value | 28.5 | 37.1 |
| Available-for-sale securities, amortized cost | $ 29.5 | $ 29.5 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of valuation reserve for inventory. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|